Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Phase 1 Completed
16 enrolled 10 charts
LAPATAM
Phase 1 Completed
20 enrolled
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 1 Completed
42 enrolled
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Phase 1 Completed
7 enrolled 8 charts
CP-724,714 in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
9 enrolled
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Phase 1 Completed
13 enrolled
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Phase 1 Completed
J65
Phase 1 Completed
39 enrolled
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
56 enrolled
BMS-247550
Phase 1 Completed
40 enrolled
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Phase 1 Completed
22 enrolled
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Phase 1 Completed
9 enrolled
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
31 enrolled
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase 1 Completed
9 enrolled
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1 Completed
12 enrolled
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Phase 1 Completed
40 enrolled
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase 1 Completed
45 enrolled
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Phase 1 Completed
50 enrolled
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
Phase 1 Completed
20 enrolled
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
19 enrolled
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
14 enrolled
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Phase 1 Completed
14 enrolled
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Phase 1 Completed
13 enrolled
PET Scans in Patients With Locally Advanced Breast Cancer
Phase 1 Completed
8 enrolled
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
33 enrolled
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
Phase 1 Completed
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Phase 1 Completed
28 enrolled
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
14 enrolled
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Phase 1 Completed
68 enrolled
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
23 enrolled
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
Phase 1 Completed
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Phase 1 Completed
12 enrolled 9 charts
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
18 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Biological Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
24 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Decitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
24 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
24 enrolled
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1 Completed
23 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled